Evidence map›Paper›PMID 37010190›Full record

ReviewCancer science2023

Autophagy and cancer: Basic mechanisms and inhibitor development.

Yutaro Hama, Yuta Ogasawara, Nobuo N Noda

Abstract readReview
In one paragraph

Review in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Targeting Lysosomes for Enhanced Anti-Cancer Therapeutics and Immune Response.International journal of biological sciences · 2026
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Chloroquine and Chemotherapeutic Compounds in Experimental Cancer Treatment.International journal of molecular sciences · 2024
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yutaro HamaInstitute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
Yuta OgasawaraInstitute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
Nobuo N NodaInstitute for Genetic Medicine, Hokkaido University, Sapporo, Japan.ORCID https://orcid.org/0000-0002-6940-8069

Funding

Core Research for Evolutional Science and Technology JPMJCR20E3Japan Society for the Promotion of Science JP19H05707Japan Society for the Promotion of Science JP21H02072Japan Society for the Promotion of Science JP21K06173Japan Society for the Promotion of Science JP22J01742Takeda Science Foundation
6 · The paper itself

Abstract

Autophagy is a lysosomal degradation system of cytoplasmic components that contributes to cellular homeostasis through the turnover of various biomolecules and organelles, often in a selective manner. Autophagy is closely related to cancer, but its roles in cancer are complicated. It works as either a promoter or suppressor, depending on the stage and type of cancer. In this review, we briefly summarize the basic mechanisms of autophagy and describe the complicated roles of autophagy in cancer. Moreover, we summarize the clinical trials of autophagy inhibitors targeting cancer and the development of more specific autophagy inhibitors for future clinical application.

Indexed as

NeoplasmsAutophagyHumansATGautophagycancerchloroquineinhibitormTORC1

Identifiers

PMID37010190
PMCPMC10323110

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.